T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Conditions:   Malignant Melanoma;   Esophageal Carcinoma;   Urothelial Cancer;   Cervical Cancer;   Breast Cancer;   Sarcoma
Interventions:   Biological: Anti-MAGE-A3-DP4 TCR;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified February 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/1KHjC6S
via IFTTT